1. Home
  2. SXI vs IBRX Comparison

SXI vs IBRX Comparison

Compare SXI & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standex International Corporation

SXI

Standex International Corporation

HOLD

Current Price

$228.41

Market Cap

2.8B

Sector

Industrials

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$2.21

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXI
IBRX
Founded
1955
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SXI
IBRX
Price
$228.41
$2.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$264.00
$9.71
AVG Volume (30 Days)
152.5K
11.5M
Earning Date
01-29-2026
11-04-2025
Dividend Yield
0.58%
N/A
EPS Growth
N/A
N/A
EPS
4.36
N/A
Revenue
$837,074,000.00
$82,555,000.00
Revenue This Year
$15.51
$667.18
Revenue Next Year
$7.04
$88.32
P/E Ratio
$53.35
N/A
Revenue Growth
18.51
1025.95
52 Week Low
$128.85
$1.83
52 Week High
$252.78
$4.27

Technical Indicators

Market Signals
Indicator
SXI
IBRX
Relative Strength Index (RSI) 44.80 49.00
Support Level $227.57 $2.17
Resistance Level $252.78 $2.50
Average True Range (ATR) 8.99 0.16
MACD -1.01 0.02
Stochastic Oscillator 9.33 35.56

Price Performance

Historical Comparison
SXI
IBRX

About SXI Standex International Corporation

Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: